VTYX — Ventyx Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease
Brief: Ventyx Biosciences Q1 EPS USD -0.39
Ventyx Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Ventyx Biosciences Q4 EPS USD -0.41
Ventyx Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview
Ventyx Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Ventyx Biosciences Q3 Net Income USD -35.249 Million
Ventyx Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-US energy sector, gold miners, AeroVironment
U.S. STOCKS ON THE MOVE-Meta, US energy sector, gold miners
Brief: Ventyx Biosciences Announces $27 Mln Investment From Sanofi
Ventyx rises on $27 million investment from Sanofi
Brief: Ventyx Biosciences Announces Initiation Of Dosing In A Phase 2A Trial Of Vtx3232 In Patients With Early Parkinson’S Disease
Ventyx Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Ventyx Biosciences Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Ventyx Biosciences Q2 Operating Expenses USD 35.712 Million
U.S. STOCKS ON THE MOVE-Bank of Marin Bancorp, ON Semiconductor, Walt Disney
U.S. STOCKS ON THE MOVE-Ventyx Biosciences, McDonald's, Pinterest
Ventyx Biosciences slumps as bowel disease drug fails in mid-stage study